Wave Life Sciences Ltd

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage biotechnology company focused on developing RNA-based medicines across multiple therapeutic modalities, including RNA interference (RNAi, using its proprietary SpiNA design) and RNA editing (using AIMers). The company's proprietary PRISM platform combines chemistry innovation with deep insights in human genetics to design oligonucleotide therapeutics for both rare and common diseases. Wave's pipeline centers on three lead programs: WVE-007, a GalNAc-siRNA targeting INHBE for obesity and cardiometabolic diseases; WVE-006, a GalNAc-RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD); and WVE-008, a GalNAc-RNA editing oligonucleotide for PNPLA3 I148M liver disease. The company also has earlier-stage programs in Duchenne muscular dystrophy (WVE-N531, exon 53 skipping) and Huntington's disease (WVE-003, allele-selective mHTT silencing). Wave has a collaboration with GSK and maintains in-house GMP manufacturing capabilities. The company is pursuing a strategy that leverages human genetic evidence to identify therapeutic targets and applies its proprietary stereopure chemistry platform to develop potentially best-in-class RNA medicines with durable activity and infrequent dosing. Updated Jul 30, 2026